Tumor News and Research

RSS

Amifostine makes radiation more effective

Doctors in Brazil have concluded that the drug amifostine eases many of the most common side effects associated with patients receiving radiation therapy to treat their cancer while simultaneously making the cancer more susceptible to radiation.

1 Mar 2006

FDA approves Rituxan (Rituximab)

Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.

1 Mar 2006

Scientists reprogramme malignant melanoma cells to become normal pigment cells

Scientists at Northwestern University and the Stowers Institute for Medical Research have reprogrammed malignant melanoma cells to become normal melanocytes, or pigment cells, a development that may hold promise in treating of one of the deadliest forms of cancer.

1 Mar 2006

Link between rheumatoid arthritis and cancer examined

Rheumatoid arthritis is an inflammatory disease of the immune system and is thought to be linked to an increased risk of cancers of the lymphatic system.

28 Feb 2006

Cervical cancer vaccines in development

Two preventative vaccines, Gardasil (Merck) and Cervarix (GlaxoSmithKline) that work against the Human Papilloma virus (HPV) - a sexually transmitted infection and the primary cause of cervical cancer - are gaining favorable attention.

27 Feb 2006

Clinical trial of new Bionovo menopause drug moves forward

Today, millions of women suffer from often-harsh symptoms of menopause such as hot flashes and night sweats -- and relief is nowhere to be found.

27 Feb 2006

New FDA approved mobile electron-beam system increases survival rates of women with advanced rectal cancer

Colorectal cancer is widely considered a man's disease, but actually affects an equal number of women and men. Detected early, it is highly curable in both genders, with survival rates approaching 90 percent. But if the cancer is detected at a more advanced stage, the outlook is often dismal.

27 Feb 2006

Ginkgo biloba reduces aggressive cancer risk in animal experiments

Researchers at Georgetown University Medical Center say they now have a clearer picture of how an extract from the leaves of the Ginkgo biloba tree reduces the risk of aggressive cancer in animal experiments.

27 Feb 2006

Androgen deprivation therapy does not prevent prostate cancer from spreading

Oregon Health & Science University Cancer Institute researchers wanted to know if depriving men of testosterone actually keeps cancer from spreading beyond the prostate.

27 Feb 2006

Study associates chronic, severe inflammation with increased lymphoma risk among RA patients

An inflammatory disease of the immune system, rheumatoid arthritis (RA) is associated with increased occurrence of lymphoma--or cancers of the lymphatic system, which plays an integral role in the body's ability to fight infection.

27 Feb 2006

$1 million of mesothelioma research funding

The Mesothelioma Applied Research Foundation (MARF) has announced awards of almost $1 million in additional research funding aimed at curing mesothelioma.

24 Feb 2006

Selective T cell stimulation could help improve treatment of autoimmune disease and cancer

The findings could also be significant for developing new ways to help patients with autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, or juvenile diabetes.

23 Feb 2006

Avastin trial for pancreatic tumors

"Our findings from the previous study suggest that the combination of chemotherapy and radiation is a safe and effective treatment method to reduce the local extent of pancreatic tumors," said Dr. Talamonti.

23 Feb 2006

Extract from Scutellaria Barbata may treat breast cancer

A new clinical formulation extracted from a botanical may provide physicians with a new tool in treating aggressive late-stage breast cancer.

21 Feb 2006

M. D. Anderson Cancer Center to investigate CTCE-9908 chemokine CXCR4 antagonist

Chemokine Therapeutics has announced that it has entered into an agreement with The University of Texas M. D. Anderson Cancer Center of Houston, Texas to study the Company's lead anti-cancer compound, CTCE-9908, a chemokine CXCR4 antagonist.

21 Feb 2006

Multikine treatment increases survival in cancer patients

CEL-SCI Corporation has announced positive results from a long-term follow-up study of head & neck cancer patients treated with its drug Multikine in a Phase II clinical trial.

21 Feb 2006

Inflammatory reaction drives hormone resistance in cancer

In the journal Cell, researchers report new evidence to explain why prostate cancer and other hormone-dependent cancers may become resistant to hormone therapies.

21 Feb 2006

Most patients have kidney removed, despite organ-sparing surgery option

A less aggressive type of surgery designed to spare healthy organ tissue is used infrequently to treat early-stage kidney cancer, according to researchers at the University of Michigan Comprehensive Cancer Center.

21 Feb 2006

Mangafodipir appears to increase the cancer-killing ability of some chemotherapy drugs

A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.

21 Feb 2006

New mechanism that regulates K-Ras - protein that plays an important role in cancer

Researchers have discovered a protein widely known to cause the out-of-control growth of cells can actually be manipulated to induce those cells to commit suicide, providing a novel target for the development of anti-cancer drugs, according to the results of a new study led by New York University School of Medicine researchers.

21 Feb 2006